Document Detail


Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
MedLine Citation:
PMID:  21782939     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
In this study, a brain-targeted chemotherapeutical delivery system, doxorubicin-loaded lactoferrin-modified procationic liposome (DOX-Lf-PCL) was developed, and its therapeutic effect for glioma was evaluated. The uptake profile of various DOX formulations in vitro by primary brain capillary endothelial cells (BCECs) and glioma cell C6 were studied by laser scanning confocal microscope and flow cytometry. An intracranial tumor model of rats was employed to evaluate the therapeutic effect of DOX-Lf-PCLs for glioma. Five groups of glioma-bearing rats (total n=50) were subjected to three cycles of 2.5mg/kg body weight of doxorubicin in different formulations or normal saline (N.S.) and analyzed for survival (median survival time, Kaplan-Meier). The results indicated that compared with the DOX solution or DOX-loaded conventional liposomes (DOX-Lips), DOX-PCLs and DOX-Lf-PCLs showed an improved performance in the uptake efficiency in BCECs and C6 cells. The DOX-Lf-PCLs can inhibit the growth of C6 more efficiently in vitro than other DOX formulations. The endocytosis involved in the DOX-Lf-PCLs uptake of C6 was mediated by both receptor- and absorption-mediated transcytosis. DOX-Lf-PCLs could significantly extend the survival time compared with the N.S. control and other DOX formulations. This study showed that the therapy with DOX-Lf-PCLs offers an effective therapeutic potential for gliomas.
Authors:
Huali Chen; Yao Qin; Qianyu Zhang; Wei Jiang; Lei Tang; Ji Liu; Qin He
Related Documents :
7023649 - A randomized prospective comparison of intermittent methotrexate, methotrexate with leu...
433999 - Remission of uterine leiomyosarcomas treated with vincristine, adriamycin, and dimethyl...
6162259 - Bleomycin infusions combined with radiotherapy in the treatment of inoperable esophagea...
2292049 - A feasibility study of intensive caf as outpatient adjuvant therapy for stage ii breast...
20568049 - Gstt1, gstm1, and gstp1 polymorphisms and chemotherapy response in locally advanced bre...
21951719 - Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical t2...
18459179 - Multidisciplinary management of colorectal brain metastases: a retrospective study.
2039839 - Concomitant adjuvant chemotherapy and radiotherapy for high risk breast cancer patients.
22274319 - A prospective randomized controlled study on multiple neoadjuvant treatments for patien...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-18
Journal Detail:
Title:  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences     Volume:  -     ISSN:  1879-0720     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-7-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9317982     Medline TA:  Eur J Pharm Sci     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier B.V.
Affiliation:
Key Laboratory of Drug Targeting, Ministry of Education, Sichuan University, Chengdu, PR China; Laboratory of Cardiovascular Diseases, West China Hospital, The State Key Laboratory of Biotherapy, Sichuan University, Chengdu, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Excellence in education and training advances competitiveness of the pharmaceutical industry in Euro...
Next Document:  WITHDRAWN: Synthesis and Characterization of Anticancer Drug and Antibody conjugated Quantum Dots as...